Chromium

Your intake

What each level of chromium does

Approximate dose-response bands. Individual response varies — these are starting points, not prescriptions.

1. Severely lowYOU ARE HERE

   0 mcg – 11.55 mcg

   Well below target. Risk of deficiency symptoms tied to glucose metabolism.

2. Insufficient

   11.55 mcg – 35 mcg

   Below the recommended daily target. Long-term adequacy not assured.

3. Adequate

   35 mcg – 52.5 mcg

   Daily target met. Standard nutritional support for glucose metabolism.

4. Therapeutic

   52.5 mcg – 70 mcg

   Common for specific health goals. Check the evidence for your situation before sustaining this level.

5. Diminishing returns

   70 mcg – +

   Past the point where extra intake typically helps. Evidence for further benefit is thin.

Close the gap

You're at 0% of your chromium target. The biggest single-serving sources to top it off:

Overview

Trace mineral whose biological essentiality has been challenged. The 1959 'glucose tolerance factor' work has not held up; EFSA's 2014 review concluded no essential function is established. The US DV (35 mcg) is legacy. Chromium picolinate is the most-studied supplement, with modest insulin-sensitivity effects in insulin-resistant adults.

Functions

• ●Historically proposed: enhances insulin receptor activity (mechanism unconfirmed)
• ●Possible role in modulating LDLR expression
• ●No undisputed essential function in human physiology

Mechanism

Older models proposed that chromium binds 'chromodulin', a low-molecular-weight chromium-binding peptide, that amplifies insulin receptor tyrosine kinase activity. Modern biochemistry has not confirmed this. If chromium has any pharmacologic effect, it is at supplemental doses (200–1,000 mcg/day) and limited to insulin-resistant subgroups.

Benefits

• ●Modest reduction in fasting glucose and HbA1c in some type 2 diabetes trials (heterogeneous)
• ●Possible mild appetite suppression in some PMS/atypical depression studies
• ●No effect on body composition in non-insulin-resistant adults
• ●EFSA does not recognise an established essential function

Deficiency

No reliable cases of spontaneous chromium deficiency in humans. A few historical TPN case reports without chromium are the only published examples.

Excess

Trivalent chromium (Cr3+, supplements) has very low toxicity at typical supplement doses. Hexavalent chromium (Cr6+, industrial pollutant) is carcinogenic — completely different category.

Forms

• Chromium picolinate
  Most studied; mild lipid and glucose effects in some trials
• Chromium polynicotinate
  Alternative organic form; similar profile
• Chromium chloride
  Inorganic; poorly absorbed
• Chromium GTF (brewer's yeast)
  Mixed organic forms; historical research substrate

Food sources

• Broccoli (cooked) · 1/2 cup11 mcg
• Grape juice · 1 cup8 mcg
• Whole-wheat English muffin · 14 mcg
• Beef (cooked) · 3 oz2 mcg
• Brewer's yeast · 1 tbsp10 mcg

Supplement forms

Chromium picolinate is the most studied. If you supplement, 200 mcg/day is a reasonable starting dose; benefits are most plausible in people with existing insulin resistance. Skipping it is also reasonable — EFSA's review found no essential function established.

Bioavailability

Only ~0.4–2.5% of dietary chromium is absorbed. Organic forms (picolinate, polynicotinate) absorb modestly better than inorganic. Vitamin C and niacin slightly enhance absorption; antacids reduce it.

Longevity relevance

Low signal. Modern essentiality is contested; supplementation effects are small and limited to insulin-resistant subgroups. Whole-food intake from a typical diet is unlikely to be a healthspan-limiting factor.

Relationships

References

• NIH ODS — Chromiumguideline
• Linus Pauling Institute — Chromiumreview
• EFSA — chromium essentiality (2014)review

About Chromium

Insulin signaling support; glucose uptake.

Role

Glucose metabolism

Daily target

35 mcg (DV)

Also called

chromium, chromium picolinate, chromium polynicotinate, chromium chloride